Moser M
Yale University School of Medicine, New Haven, Connecticut.
J Hum Hypertens. 1993 Feb;7 Suppl 1:S16-20.
Clinical experience indicates that carvedilol, a beta-blocker with vasodilating properties, is effective as once daily monotherapy in both young and elderly hypertensives. Titration is simple to an effective dosage, and response rates appear to be equivalent to those noted with other monotherapeutic agents presently recommended as initial therapy in hypertension. The drug is well tolerated by the majority of patients. No significant metabolic changes have been noted with carvedilol in short-term studies. Additional research is ongoing to determine the long-term effectiveness of this new antihypertensive agent.
临床经验表明，卡维地洛是一种具有血管舒张特性的β受体阻滞剂，作为每日一次的单一疗法，对年轻和老年高血压患者均有效。滴定至有效剂量很简单，其有效率似乎与目前推荐作为高血压初始治疗的其他单一治疗药物相当。大多数患者对该药物耐受性良好。在短期研究中，未发现卡维地洛有明显的代谢变化。正在进行进一步研究以确定这种新型抗高血压药物的长期疗效。
